Bluerock Value Exchange

Business news, market intelligence, and global industry analysis.

The Latest

Netmarble Corporation bets on staged rollout to de-risk The Seven Deadly Sins: Origin open-world expansion

The real reason Netmarble is launching The Seven Deadly Sins: Origin in phases

Longeveron Inc. appoints Stephen H. Willard as CEO ahead of pivotal Phase 2b stem cell data

Philadelphia jury orders Johnson & Johnson to pay $250,000 in talc powder lawsuit

Representative image showing the intersection of financial performance and cancer diagnostics, reflecting Exact Sciences’ record 2025 results and its pending acquisition by Abbott Laboratories.

Exact Sciences (NASDAQ: EXAS) earnings show why Abbott moved now on a $21bn diagnostics acquisition

Bluerock Value Exchange unveils $71mn BR Diversified Industrial Portfolio 6 DST targeting high-growth Sunbelt markets

Bluerock Value Exchange launches a $71M industrial DST portfolio in the Sunbelt, offering investors stable cash flow, rent growth potential, and tax benefits.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

September 4, 2025